{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT05166577",
            "orgStudyIdInfo": {
                "id": "VT3996-301"
            },
            "organization": {
                "fullName": "Viracta Therapeutics, Inc.",
                "class": "INDUSTRY"
            },
            "briefTitle": "Nanatinostat Plus Valganciclovir in Patients With Advanced EBV+ Solid Tumors, and in Combination With Pembrolizumab in EBV+ RM-NPC",
            "officialTitle": "An Open-Label, Multicenter Phase 1b/2 Study of Nanatinostat and Valganciclovir in Patients With Advanced Epstein-Barr Virus-Positive (EBV+) Solid Tumors and in Combination With Pembrolizumab in Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma",
            "therapeuticArea": [
                "Oncology and Hematology",
                "Other"
            ],
            "study": "nanatinostat-plus-valganciclovir-in-patients-with-advanced-ebv-solid-tumors-and-in-combination-with-pembrolizumab-in-ebv-rm-npc"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-07",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2021-10-08",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2024-12",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2025-10",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2021-12-03",
            "studyFirstSubmitQcDate": "2021-12-20",
            "studyFirstPostDateStruct": {
                "date": "2021-12-22",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-07-11",
            "lastUpdatePostDateStruct": {
                "date": "2024-07-15",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Viracta Therapeutics, Inc.",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "This study will evaluate the safety and efficacy of nanatinostat in combination with valganciclovir in patients with relapsed/refractory EBV-positive solid tumors and in combination with pembrolizumab in patients with recurrent/metastatic nasopharyngeal carcinoma",
            "detailedDescription": "This is an open-label, multicenter Phase 1b/2 study evaluating nanatinostat in combination with valganciclovir alone and in combination with pembrolizumab. Nanatinostat is a selective class I HDAC inhibitor which induces EBV early lytic phase protein generation, activating (val)ganciclovir to its cytotoxic form.\n\nThe Phase 1b dose escalation portion is designed to evaluate safety and to determine the recommended Phase 2 dose (RP2D) in patients with EBV+ RM-NPC followed by a Project Optimus \\| FDA (https://www.fda.gov/about-fda/oncology-center-excellence/project-optimus) cohort to confirm the RP2D. Up to 60 patients with EBV+ RM-NPC will be randomized 1:1 to receive nanatinostat in combination with valganciclovir at the confirmed RP2D with or without pembrolizumab to evaluate safety, overall response rate, and potential pharmacodynamic markers in the Phase 2 dose expansion part of the study. Additionally, patients with other EBV+ solid tumors will be enrolled to receive nanatinostat in combination with valganciclovir at the RP2D in a Phase 1b cohort."
        },
        "conditionsModule": {
            "conditions": [
                "Nasopharyngeal Carcinoma",
                "EBV-Related Gastric Carcinoma",
                "EBV-Related Leiomyosarcoma",
                "EBV Related Carcinoma",
                "EBV-Related Sarcoma"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1",
                "PHASE2"
            ],
            "designInfo": {
                "allocation": "RANDOMIZED",
                "interventionModel": "PARALLEL",
                "interventionModelDescription": "A traditional 3+3 dose escalation design followed first by a dose optimization cohort and then by dose expansion with 1:1 randomization to receive nanatinostat and valganciclovir with or without pembrolizumab in Phase 2.",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 130,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Nanatinostat in combination with valganciclovir",
                    "type": "EXPERIMENTAL",
                    "interventionNames": [
                        "Drug: Nanatinostat",
                        "Drug: Valganciclovir"
                    ]
                },
                {
                    "label": "Nanatinostat in combination with valganciclovir and pembrolizumab",
                    "type": "EXPERIMENTAL",
                    "interventionNames": [
                        "Drug: Nanatinostat",
                        "Drug: Valganciclovir",
                        "Drug: Pembrolizumab"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "Nanatinostat",
                    "description": "Nanatinostat dose escalation starting at 20 mg orally daily, 4 days per week",
                    "armGroupLabels": [
                        "Nanatinostat in combination with valganciclovir"
                    ],
                    "otherNames": [
                        "VRx-3996"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Nanatinostat",
                    "description": "Nanatinostat at the confirmed RP2D",
                    "armGroupLabels": [
                        "Nanatinostat in combination with valganciclovir and pembrolizumab"
                    ],
                    "otherNames": [
                        "VRx-3996"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Valganciclovir",
                    "description": "Valganciclovir starting at 900 mg orally daily",
                    "armGroupLabels": [
                        "Nanatinostat in combination with valganciclovir",
                        "Nanatinostat in combination with valganciclovir and pembrolizumab"
                    ],
                    "otherNames": [
                        "Valcyte"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Pembrolizumab",
                    "description": "Pembrolizumab (anti-PD-1) dosed at 200 mg intravenous (IV) every 3 weeks",
                    "armGroupLabels": [
                        "Nanatinostat in combination with valganciclovir and pembrolizumab"
                    ],
                    "otherNames": [
                        "Keytruda"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Phase 1b: Incidence of dose-limiting toxicities (DLTs)",
                    "timeFrame": "DLT period of 28 Days"
                },
                {
                    "measure": "Phase 2: Overall response rate (ORR)",
                    "timeFrame": "Approximately 3 years"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Incidence and severity of adverse events",
                    "timeFrame": "Approximately 28 days following the last dose"
                },
                {
                    "measure": "Duration of response (DOR)",
                    "timeFrame": "Approximately 3 years"
                },
                {
                    "measure": "Disease control rate (DCR)",
                    "timeFrame": "Approximately 3 years"
                },
                {
                    "measure": "Progression-free survival (PFS)",
                    "timeFrame": "Approximately 3 years"
                },
                {
                    "measure": "Overall survival (OS)",
                    "timeFrame": "Approximately 3 years"
                },
                {
                    "measure": "Pharmacokinetic parameter - time to maximum plasma concentration [tmax]",
                    "timeFrame": "Approximately at 28 days following enrollment"
                },
                {
                    "measure": "Pharmacokinetic parameter - maximum plasma concentration [Cmax]",
                    "timeFrame": "Approximately 28 days following enrollment"
                },
                {
                    "measure": "Pharmacokinetic parameter - area under the plasma concentration-time curve [AUC]",
                    "timeFrame": "Approximately 28 days following enrollment"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Key Inclusion Criteria:\n\n* Recurrent or metastatic EBV+ nasopharyngeal carcinoma (RM-NPC) for whom no potentially curative options are available, who have received at least 1 prior line of platinum-based chemotherapy and no more than 3 prior lines of therapy for RM-NPC.\n* Phase 1b exploratory proof-of-concept cohort only: Advanced/metastatic EBV+ non-NPC solid tumors with no available curative therapies.\n* Measurable disease per RECIST v1.1\n* ECOG performance status 0 or 1\n* Adequate bone marrow and liver function\n\nKey Exclusion Criteria:\n\n* Anti-tumor treatment with cytotoxic drugs, biologic therapy, immunotherapy, or other investigational drugs within 4 weeks or \\>5 half-lives, whichever is shorter\n* Active CNS disease\n* Inability to take oral medication, malabsorption syndrome or any other gastrointestinal condition (nausea, diarrhea, vomiting) that may impact the absorption of nanatinostat and valganciclovir\n* Active infection requiring systemic therapy\n* Active autoimmune disease that has required systemic therapy with modifying agents, corticosteroids, or immunosuppressive agents\n* Positive hepatitis B or hepatitis C",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Afton Katkov, MSc",
                    "role": "CONTACT",
                    "phone": "858-400-8470",
                    "email": "ClinicalTrials@Viracta.com"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Darrel P Cohen, MD, PhD",
                    "affiliation": "Viracta Therapeutics",
                    "role": "STUDY_DIRECTOR"
                }
            ],
            "locations": [
                {
                    "facility": "The Oncology Institute of Hope and Innovation",
                    "status": "WITHDRAWN",
                    "city": "Lynwood",
                    "state": "California",
                    "zip": "90262",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 33.93029,
                        "lon": -118.21146
                    }
                },
                {
                    "facility": "Stanford Cancer Center",
                    "status": "RECRUITING",
                    "city": "Stanford",
                    "state": "California",
                    "zip": "94305",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "A. Dimitrios Colevas, M.D.",
                            "role": "CONTACT",
                            "phone": "650-498-6000"
                        },
                        {
                            "name": "Savanna Biedermann",
                            "role": "CONTACT",
                            "phone": "650-497-7418",
                            "email": "sbiedermann@stanford.edu"
                        }
                    ],
                    "geoPoint": {
                        "lat": 37.42411,
                        "lon": -122.16608
                    }
                },
                {
                    "facility": "University of Colorado Hospital",
                    "status": "RECRUITING",
                    "city": "Aurora",
                    "state": "Colorado",
                    "zip": "80045",
                    "country": "United States",
                    "contacts": [
                        {
                            "role": "CONTACT",
                            "email": "ClinicalTrials@Viracta.com"
                        }
                    ],
                    "geoPoint": {
                        "lat": 39.72943,
                        "lon": -104.83192
                    }
                },
                {
                    "facility": "University of Texas MD Anderson Cancer Center",
                    "status": "RECRUITING",
                    "city": "Houston",
                    "state": "Texas",
                    "zip": "77030",
                    "country": "United States",
                    "contacts": [
                        {
                            "role": "CONTACT",
                            "email": "ClinicalTrials@Viracta.com"
                        }
                    ],
                    "geoPoint": {
                        "lat": 29.76328,
                        "lon": -95.36327
                    }
                },
                {
                    "facility": "Blacktown Hospital",
                    "status": "RECRUITING",
                    "city": "Blacktown",
                    "country": "Australia",
                    "contacts": [
                        {
                            "role": "CONTACT",
                            "email": "ClinicalTrials@Viracta.com"
                        }
                    ],
                    "geoPoint": {
                        "lat": -33.76667,
                        "lon": 150.91667
                    }
                },
                {
                    "facility": "Macquarie University",
                    "status": "RECRUITING",
                    "city": "Sydney",
                    "country": "Australia",
                    "contacts": [
                        {
                            "role": "CONTACT",
                            "email": "ClinicalTrials@Viracta.com"
                        }
                    ],
                    "geoPoint": {
                        "lat": -33.86785,
                        "lon": 151.20732
                    }
                },
                {
                    "facility": "Princess Margaret Cancer Centre",
                    "status": "RECRUITING",
                    "city": "Toronto",
                    "country": "Canada",
                    "contacts": [
                        {
                            "role": "CONTACT",
                            "email": "ClinicalTrials@Viracta.com"
                        }
                    ],
                    "geoPoint": {
                        "lat": 43.70011,
                        "lon": -79.4163
                    }
                },
                {
                    "facility": "Queen Mary Hospital",
                    "status": "RECRUITING",
                    "city": "Hong Kong",
                    "country": "Hong Kong",
                    "contacts": [
                        {
                            "role": "CONTACT",
                            "email": "ClinicalTrials@Viracta.com"
                        }
                    ],
                    "geoPoint": {
                        "lat": 22.27832,
                        "lon": 114.17469
                    }
                },
                {
                    "facility": "Hong Kong United Oncology Centre",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Kowloon",
                    "country": "Hong Kong",
                    "contacts": [
                        {
                            "role": "CONTACT",
                            "email": "ClinicalTrials@Viracta.com"
                        }
                    ],
                    "geoPoint": {
                        "lat": 22.31667,
                        "lon": 114.18333
                    }
                },
                {
                    "facility": "Prince Of Wales Hospital, The Chinese University Of Hong Kong",
                    "status": "RECRUITING",
                    "city": "Sha Tin",
                    "country": "Hong Kong",
                    "contacts": [
                        {
                            "role": "CONTACT",
                            "email": "ClinicalTrials@Viracta.com"
                        }
                    ],
                    "geoPoint": {
                        "lat": 22.38333,
                        "lon": 114.18333
                    }
                },
                {
                    "facility": "Samsung Medical Center",
                    "status": "RECRUITING",
                    "city": "Seoul",
                    "country": "Korea, Republic of",
                    "contacts": [
                        {
                            "role": "CONTACT",
                            "email": "ClinicalTrials@Viracta.com"
                        }
                    ],
                    "geoPoint": {
                        "lat": 37.566,
                        "lon": 126.9784
                    }
                },
                {
                    "facility": "The Catholic University of Korea, Seoul St. Mary's Hospital",
                    "status": "RECRUITING",
                    "city": "Seoul",
                    "country": "Korea, Republic of",
                    "contacts": [
                        {
                            "role": "CONTACT",
                            "email": "ClinicalTrials@Viracta.com"
                        }
                    ],
                    "geoPoint": {
                        "lat": 37.566,
                        "lon": 126.9784
                    }
                },
                {
                    "facility": "Sarawak General Hospital",
                    "status": "RECRUITING",
                    "city": "Kuching",
                    "state": "Sarawak",
                    "country": "Malaysia",
                    "contacts": [
                        {
                            "role": "CONTACT",
                            "email": "ClinicalTrials@Viracta.com"
                        }
                    ],
                    "geoPoint": {
                        "lat": 1.54999,
                        "lon": 110.33333
                    }
                },
                {
                    "facility": "University of Malaya Medical Centre",
                    "status": "RECRUITING",
                    "city": "Kuala Lumpur",
                    "country": "Malaysia",
                    "contacts": [
                        {
                            "role": "CONTACT",
                            "email": "ClinicalTrials@Viracta.com"
                        }
                    ],
                    "geoPoint": {
                        "lat": 3.1412,
                        "lon": 101.68653
                    }
                },
                {
                    "facility": "National Cancer Institute (Institut Kanser Negara)",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Putrajaya",
                    "country": "Malaysia",
                    "contacts": [
                        {
                            "role": "CONTACT",
                            "email": "ClinicalTrials@Viracta.com"
                        }
                    ],
                    "geoPoint": {
                        "lat": 2.93527,
                        "lon": 101.69112
                    }
                },
                {
                    "facility": "National Cancer Centre Singapore",
                    "status": "RECRUITING",
                    "city": "Singapore",
                    "country": "Singapore",
                    "contacts": [
                        {
                            "role": "CONTACT",
                            "email": "ClinicalTrials@Viracta.com"
                        }
                    ],
                    "geoPoint": {
                        "lat": 1.28967,
                        "lon": 103.85007
                    }
                },
                {
                    "facility": "Tan Tock Seng Hospital",
                    "status": "RECRUITING",
                    "city": "Singapore",
                    "country": "Singapore",
                    "contacts": [
                        {
                            "role": "CONTACT",
                            "email": "ClinicalTrials@Viracta.com"
                        }
                    ],
                    "geoPoint": {
                        "lat": 1.28967,
                        "lon": 103.85007
                    }
                },
                {
                    "facility": "National Taiwan University Hospital",
                    "status": "RECRUITING",
                    "city": "Taipei City",
                    "country": "Taiwan",
                    "contacts": [
                        {
                            "role": "CONTACT",
                            "email": "ClinicalTrials@Viracta.com"
                        }
                    ],
                    "geoPoint": {
                        "lat": 25.04776,
                        "lon": 121.53185
                    }
                },
                {
                    "facility": "Taipei Veterans General Hospital",
                    "status": "RECRUITING",
                    "city": "Taipei City",
                    "country": "Taiwan",
                    "contacts": [
                        {
                            "role": "CONTACT",
                            "email": "ClinicalTrials@Viracta.com"
                        }
                    ],
                    "geoPoint": {
                        "lat": 25.04776,
                        "lon": 121.53185
                    }
                },
                {
                    "facility": "Mackay Memorial Hospital",
                    "status": "RECRUITING",
                    "city": "Taipei",
                    "country": "Taiwan",
                    "contacts": [
                        {
                            "role": "CONTACT",
                            "email": "ClinicalTrials@Viracta.com"
                        }
                    ],
                    "geoPoint": {
                        "lat": 25.04776,
                        "lon": 121.53185
                    }
                },
                {
                    "facility": "Linkou Chang Gung Memorial Hospital",
                    "status": "RECRUITING",
                    "city": "Taoyuan City",
                    "country": "Taiwan",
                    "contacts": [
                        {
                            "role": "CONTACT",
                            "email": "ClinicalTrials@Viracta.com"
                        }
                    ],
                    "geoPoint": {
                        "lat": 24.95233,
                        "lon": 121.20193
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000002277",
                    "term": "Carcinoma"
                },
                {
                    "id": "D000077274",
                    "term": "Nasopharyngeal Carcinoma"
                },
                {
                    "id": "D000007890",
                    "term": "Leiomyosarcoma"
                },
                {
                    "id": "D000013274",
                    "term": "Stomach Neoplasms"
                }
            ],
            "ancestors": [
                {
                    "id": "D000009375",
                    "term": "Neoplasms, Glandular and Epithelial"
                },
                {
                    "id": "D000009370",
                    "term": "Neoplasms by Histologic Type"
                },
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                },
                {
                    "id": "D000012509",
                    "term": "Sarcoma"
                },
                {
                    "id": "D000018204",
                    "term": "Neoplasms, Connective and Soft Tissue"
                },
                {
                    "id": "D000009303",
                    "term": "Nasopharyngeal Neoplasms"
                },
                {
                    "id": "D000010610",
                    "term": "Pharyngeal Neoplasms"
                },
                {
                    "id": "D000010039",
                    "term": "Otorhinolaryngologic Neoplasms"
                },
                {
                    "id": "D000006258",
                    "term": "Head and Neck Neoplasms"
                },
                {
                    "id": "D000009371",
                    "term": "Neoplasms by Site"
                },
                {
                    "id": "D000009302",
                    "term": "Nasopharyngeal Diseases"
                },
                {
                    "id": "D000010608",
                    "term": "Pharyngeal Diseases"
                },
                {
                    "id": "D000009057",
                    "term": "Stomatognathic Diseases"
                },
                {
                    "id": "D000010038",
                    "term": "Otorhinolaryngologic Diseases"
                },
                {
                    "id": "D000009379",
                    "term": "Neoplasms, Muscle Tissue"
                },
                {
                    "id": "D000005770",
                    "term": "Gastrointestinal Neoplasms"
                },
                {
                    "id": "D000004067",
                    "term": "Digestive System Neoplasms"
                },
                {
                    "id": "D000004066",
                    "term": "Digestive System Diseases"
                },
                {
                    "id": "D000005767",
                    "term": "Gastrointestinal Diseases"
                },
                {
                    "id": "D000013272",
                    "term": "Stomach Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M10902",
                    "name": "Leiomyosarcoma",
                    "asFound": "Leiomyosarcoma",
                    "relevance": "HIGH"
                },
                {
                    "id": "M5534",
                    "name": "Carcinoma",
                    "asFound": "Carcinoma",
                    "relevance": "HIGH"
                },
                {
                    "id": "M14850",
                    "name": "Recurrence",
                    "relevance": "LOW"
                },
                {
                    "id": "M15327",
                    "name": "Sarcoma",
                    "relevance": "LOW"
                },
                {
                    "id": "M16064",
                    "name": "Stomach Neoplasms",
                    "asFound": "Gastric Carcinoma",
                    "relevance": "HIGH"
                },
                {
                    "id": "M1730",
                    "name": "Nasopharyngeal Carcinoma",
                    "asFound": "Nasopharyngeal Carcinoma",
                    "relevance": "HIGH"
                },
                {
                    "id": "M17522",
                    "name": "Virus Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M21881",
                    "name": "Epstein-Barr Virus Infections",
                    "relevance": "LOW"
                },
                {
                    "id": "M12320",
                    "name": "Neoplasms, Glandular and Epithelial",
                    "relevance": "LOW"
                },
                {
                    "id": "M12315",
                    "name": "Neoplasms by Histologic Type",
                    "relevance": "LOW"
                },
                {
                    "id": "M20350",
                    "name": "Neoplasms, Connective and Soft Tissue",
                    "relevance": "LOW"
                },
                {
                    "id": "M12254",
                    "name": "Nasopharyngeal Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M13517",
                    "name": "Pharyngeal Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M12962",
                    "name": "Otorhinolaryngologic Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M9348",
                    "name": "Head and Neck Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M12253",
                    "name": "Nasopharyngeal Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M13515",
                    "name": "Pharyngeal Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M12017",
                    "name": "Stomatognathic Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M12961",
                    "name": "Otorhinolaryngologic Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M7256",
                    "name": "Digestive System Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M8886",
                    "name": "Gastrointestinal Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M7255",
                    "name": "Digestive System Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M8883",
                    "name": "Gastrointestinal Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M16062",
                    "name": "Stomach Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "T3367",
                    "name": "Leiomyosarcoma",
                    "asFound": "Leiomyosarcoma",
                    "relevance": "HIGH"
                },
                {
                    "id": "T5284",
                    "name": "Soft Tissue Sarcoma",
                    "relevance": "LOW"
                },
                {
                    "id": "T4047",
                    "name": "Nasopharyngeal Carcinoma",
                    "asFound": "Nasopharyngeal Carcinoma",
                    "relevance": "HIGH"
                },
                {
                    "id": "T5486",
                    "name": "Stomach Cancer",
                    "asFound": "Gastric Carcinoma",
                    "relevance": "HIGH"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC23",
                    "name": "Symptoms and General Pathology"
                },
                {
                    "abbrev": "BC06",
                    "name": "Digestive System Diseases"
                },
                {
                    "abbrev": "BC07",
                    "name": "Mouth and Tooth Diseases"
                },
                {
                    "abbrev": "BC09",
                    "name": "Ear, Nose, and Throat Diseases"
                },
                {
                    "abbrev": "BC01",
                    "name": "Infections"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "D000077562",
                    "term": "Valganciclovir"
                },
                {
                    "id": "C000582435",
                    "term": "Pembrolizumab"
                }
            ],
            "ancestors": [
                {
                    "id": "D000074322",
                    "term": "Antineoplastic Agents, Immunological"
                },
                {
                    "id": "D000000970",
                    "term": "Antineoplastic Agents"
                },
                {
                    "id": "D000082082",
                    "term": "Immune Checkpoint Inhibitors"
                },
                {
                    "id": "D000045504",
                    "term": "Molecular Mechanisms of Pharmacological Action"
                },
                {
                    "id": "D000000998",
                    "term": "Antiviral Agents"
                },
                {
                    "id": "D000000890",
                    "term": "Anti-Infective Agents"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M349416",
                    "name": "Pembrolizumab",
                    "asFound": "Mg/m2",
                    "relevance": "HIGH"
                },
                {
                    "id": "M1840",
                    "name": "Valganciclovir",
                    "asFound": "Levofloxacin",
                    "relevance": "HIGH"
                },
                {
                    "id": "M1346",
                    "name": "Antineoplastic Agents, Immunological",
                    "relevance": "LOW"
                },
                {
                    "id": "M2342",
                    "name": "Immune Checkpoint Inhibitors",
                    "relevance": "LOW"
                },
                {
                    "id": "M4314",
                    "name": "Antiviral Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M4214",
                    "name": "Anti-Infective Agents",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "ANeo",
                    "name": "Antineoplastic Agents"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                },
                {
                    "abbrev": "Infe",
                    "name": "Anti-Infective Agents"
                }
            ]
        }
    },
    "hasResults": false
}